Dyno Therapeutics Unveils AI-Engineered AAV Vector Dyno-bn8 for Muscle Gene Therapy with 25-Fold Dose Reduction
Key Insights
Dyno Therapeutics (search) announced Dyno-bn8 (search), a novel AAV (search) gene delivery vector that achieves therapeutic muscle delivery at 5.2e12 vg/kg, representing a 25-fold dose reduction compared to existing muscle gene therapies.
Non-human primate studies demonstrated that Dyno-bn8 (search) transduced 81% of skeletal muscle (search) cells and 20% of cardiac cells while significantly reducing liver (search) accumulation compared to current vectors.
The AI-engineered capsid outperformed existing muscle-targeted vectors in head-to-head comparisons and shows compatibility with human muscle cells, positioning it for clinical translation.
Dyno Therapeutics (search) has unveiled Dyno-bn8 (search), a breakthrough adeno-associated virus (AAV (search)) gene delivery vector that could transform muscle gene therapy by achieving therapeutic delivery at dramatically reduced doses. The AI-engineered capsid enables systemic treatment of muscle and neuromuscular diseases (search) at 5.2e12 vg/kg, a 25-fold reduction compared to existing muscle gene therapies dosed at 1.33e14 vg/kg.
The announcement, made at Dyno's Genetic Agency Technology Conference (GATC), represents a significant advancement in addressing the key limitations that have hindered muscle gene therapy development. Current AAV (search) vectors require high doses to achieve therapeutic levels and preferentially accumulate in the liver (search), potentially causing toxicity through liver damage or immunological responses.
AI-Driven Design Breakthrough
Dyno scientists developed Dyno-bn8 (search) by training AI sequence design models using proprietary non-human primate (NHP) performance data for millions of capsids. This approach created a novel AAV (search) capsid with broad tropism to muscle cells, substantial liver (search) detargeting, and straightforward manufacturability.
"For 10 years, we've been working day and night to achieve therapeutic delivery to both skeletal and cardiac muscle (search) at low doses while dramatically reducing off-target liver (search) exposure. Dyno-bn8 (search) now leads the field for muscle delivery," said Eric Kelsic, Ph.D., CEO and Cofounder of Dyno Therapeutics (search). "By solving the grand challenges that have kept genetic medicines out of reach for so many, Dyno is becoming the partner of choice for developers of breakthrough genetic medicines."
Superior Performance in Primate Studies
In NHP studies, Dyno-bn8 (search) demonstrated exceptional muscle targeting efficiency. When administered systemically at 5.2e12 vg/kg, the capsid transduced 81% of target skeletal muscle (search) cells and 20% of cardiac cells throughout the body. In head-to-head comparisons, Dyno-bn8 outperformed MyoAAV-4E (search), a previously published capsid, in both muscle tropism and liver (search) detargeting.
The improved performance profile offers dual benefits: lower manufacturing costs for curative gene therapy doses and enhanced safety through reduced dosing and engineered liver (search) detargeting.
Clinical Readiness and Human Translatability
Dyno reported several key findings supporting Dyno-bn8 (search)'s clinical potential. The company identified a highly conserved receptor that confers enhanced muscle tropism and demonstrated that Dyno-bn8 interacts with both NHP and human orthologs. The enhanced muscle tropism was also confirmed in vitro using human muscle cell lines, providing evidence for human translatability.
Manufacturing advantages further support clinical development. Dyno-bn8 (search) can be easily manufactured at large scale and is compatible with existing AAV9-based processes, streamlining production and reducing the uncertainty and delays that frequently affect gene therapy development.
Expanding Portfolio of Gene Delivery Solutions
Dyno-bn8 (search) joins Dyno's growing portfolio of specialized AAV (search) capsids, including Dyno-3hv for neuromuscular delivery, Dyno-4z2 for ocular delivery, and Dyno-ahq for central nervous system delivery. These off-the-shelf AAV gene delivery solutions are available for licensing by therapeutic developers and through the Dyno Frontiers Program for novel payload strategy demonstrations.
The company's mission focuses on building high-performance genetic technologies through AI-driven approaches to gene delivery and sequence design. Dyno maintains strategic collaborations with leading gene therapy developers Astellas and Roche, as well as technology partnerships including NVIDIA (search), to ensure broad accessibility of these life-transforming technologies.